Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 + Fluzoparib in HER2-Expressing Advanced Solid Tumors
NCT05349409Phase 2Unknown
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Jun 2022
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan in HER2-positive cancer (HER2+), sponsored by Suzhou Suncadia Biopharmaceutical. Status: unknown.
02
Drugs
trastuzumab rezetecan
03
Conditions
HER2-positive cancer (HER2+)
Beyond the preview
Go deeper on NCT05349409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05349409.